CABOZANTINE COULD BE THE ANSWER IN PAPILLARY RENAL CANCER AND ANGIOSARCOMA.

Based on the fact that Cabozantine is an inhibitor of RET, MET,VEGF 1through 3, KIT, TRKB, FLT and TIE-2.   It needs to be tried in papillary renal cancer, angiosarcoma, and VHL were amplification of MET is important.  in VHL however, proof of concept studies should be done when Cabozantine is combine to MTOR or Velcade.

Cabozantine and Velcade would have an exclusive role in Myeloma

cabozantine and MTOR would have an exclusive role in Clear Cell Renal cancer
 A role in Pheochromocytoma is anticipated!